Indivior stock trades below analyst targets as valuation gap persists

Indivior stock (ISIN GB00BYZ0C031) is trading near USD 34.88 on Nasdaq as of September 20, 2026, keeping the specialty pharmaceuticals group at a mid-cap valuation that still falls noticeably short of analysts’ average 12-month price target around USD 45.17. As MarketBeat reported on September 20, 2026, the consensus recommendation on Indivior is Moderate Buy, with the average 1-year target price at USD 45.1667, implying potential upside of roughly 29.6 percent from the USD 34.88 level.

Analyst targets signal upside

According to Ad-hoc-news on September 20, 2026, MarketBeat data show that seven firms currently cover Indivior with a consensus Moderate Buy rating and an average 12-month target of USD 45.1667, about USD 10.29 above the USD 34.88 opening level referenced in the same overview. This gap of approximately 29.6 percent between the current share price and the analyst target range is one of the key valuation signals investors are watching, especially for those considering longer holding periods in the specialty pharmaceuticals segment.

The same Ad-hoc-news summary highlights that at USD 34.88 as of September 20, 2026, Indivior’s market capitalization stands around USD 4.4 billion in US dollars, placing the company firmly in the mid-cap bracket on Nasdaq. At that valuation, the shares trade below both the USD 40.63 model-derived fair value cited by Faircurve as of September 19, 2026 and the USD 45.1667 average broker target, leaving room for the price to move depending on how upcoming earnings releases and regulatory developments shape sentiment.

Valuation models and fundamentals context

As Ad-hoc-news summarized from a Faircurve healthcare sector screen dated September 19, 2026, Indivior is shown with a last close of USD 34.88 and a model-derived fair value of USD 40.63, implying a positive valuation gap of 16.5 percent in that framework. While the Faircurve classification comes with low model confidence, it reinforces the view that the shares are trading at a discount to estimated intrinsic value, adding another quantified comparison alongside the roughly 29.6 percent spread to the average broker target.

Fundamental figures for Indivior’s most recent reporting periods are not detailed in the latest valuation-focused overviews, but for investors the central point is that future cash flows and margins in its addiction treatment and psychiatry portfolio will determine whether the current discount closes. The fact that the average analyst target at USD 45.1667 is above both the USD 40.63 model fair value and the USD 34.88 market level signals that covering banks expect earnings and pipeline progress to support a higher price over the coming 12 months than the fair value model alone suggests.

Stock price level and trading data

Indivior’s primary listing is on Nasdaq in the United States, where the stock most recently opened at USD 34.88 according to the MarketBeat-derived overview cited by Ad-hoc-news on September 20, 2026. In that snapshot, the shares are described as trading near USD 34.88, a level that sits comfortably within the current 52-week band and does not represent an extreme high or low for the period. The same commentary notes a market capitalization of roughly USD 4.4 billion as of September 19, 2026, reflecting investors’ aggregate valuation of the company’s future earnings and risk profile at the prevailing price.

Earlier commentary from Ad-hoc-news on September 21, 2026 referenced a Nasdaq closing price for Indivior stock of USD 34.88 on September 18, 2026, describing the session as essentially flat versus the prior day with an implied daily change of about 0.0 percent and intraday moves confined within a narrow band in the mid-30s USD. That description underscores how the stock has recently traded sideways rather than showing large swings, even as valuation models and analyst targets suggest upside potential if fundamentals develop as expected.

Risks and what investors are watching

For investors, the combination of a USD 34.88 share price as of September 20, 2026, a USD 40.63 model fair value as of September 19, 2026 and an average analyst target of USD 45.1667 highlights a structured set of expectations about Indivior’s future performance. The quantified gaps of 16.5 percent to model fair value and around 29.6 percent to the broker target summarise the valuation case, but they also implicitly contain risk: if future earnings, regulatory outcomes or competitive dynamics in addiction treatment and psychiatry diverge from current assumptions, the shares could remain around the present level or even move lower instead of converging towards those higher reference points.

Analyst and model-based classifications tend to emphasize earnings quality, balance sheet strength and regulatory visibility in pharmaceuticals, so key checkpoints for Indivior will include its next scheduled results release and any updates on litigation or product approvals. With the stock trading below both model and broker targets but not at a distressed level within its 52-week range, many investors are likely to treat upcoming fundamentals and regulatory news as decisive factors for whether the valuation discount narrows or persists over the coming quarters.

Indivior stock price snapshot

As of September 20, 2026, Indivior stock is indicated at around USD 34.88 on Nasdaq, with a market capitalization of approximately USD 4.4 billion in US dollars based on that price level. In recent sessions, including the September 18, 2026 close at USD 34.88 that Ad-hoc-news described as essentially flat, the shares have remained within their established 52-week range and have not tested either an annual high or low, suggesting a relatively stable trading pattern in the short term even as valuation metrics point to potential upside over a longer horizon.

More news and analyses on Indivior stock